Bristol-Myers Squibb Company (NYSE:BMY) is included in our list of the best stocks to buy for financial stability.
Bristol-Myers Squibb Company (NYSE:BMY) is facing mixed analyst sentiment, with roughly 60% of covering analysts maintaining mixed ratings on the stock. At the same time, the consensus price target of $63 implies 10% upside.
The recent analyst update came from HSBC, in which analysts emphasized the healthcare sector’s greater resilience relative to the broader market amid heightened macro uncertainty tied to rising geopolitical risks. Furthermore, the firm’s analysts noted limited impact from AI disruption on healthcare stocks.
Looking ahead, the firm remains confident in Bristol-Myers Squibb Company’s (NYSE:BMY) outlook as it expects the sector’s resilience to play a crucial role in driving the stock’s outperformance in the coming quarter.
Accordingly, HSBC boosted its price target on the stock from $53 to $60. As of March 17, 2026, the firm maintains a “Hold” rating on Bristol-Myers Squibb Company (NYSE:BMY).
The analyst update follows the company’s positive late-stage trial results for its experimental oral drug mezigdomide in combination with carfilzomib and dexamethasone for relapsed multiple myeloma. According to the press release dated March 9, 2026, mezigdomide achieved a significant improvement in patient survival compared to the standard regimen. Furthermore, it showed no increased risk of disease worsening and was consistent with its established safety profile.
Commenting on the results, analysts at RBC Capital described the data as an incremental positive, with the American Cancer Society projecting roughly 36,000 new U.S. multiple myeloma cases in 2026, which reflects the therapy’s market potential.
Bristol-Myers Squibb Company (NYSE:BMY) engages in the development and marketing of biopharmaceuticals, including small molecules, biologics, and CAR-T therapies. The company’s focus remains on discovering innovative treatments for oncology, hematology, and other specialty disease areas globally.
While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
